Ptc Therapeutics (PTCT) Other Operating Expenses (2012 - 2026)

Ptc Therapeutics' Other Operating Expenses history runs 12 years deep, the most recent figure standing at $40.5 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 4967.0% year-over-year to $40.5 million in Q1 2026; TTM through Mar 2026 was $40.5 million, a 683.3% increase from a year earlier, with the FY2025 full-year figure at $800000.0, down 82.12% from the prior year.
• Other Operating Expenses rose to $40.5 million in Q1 2026 per PTCT's latest filing, from $800000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $128.9 million in Q2 2023 and bottomed at -$6.3 million in Q4 2022.
• The 5-year median for Other Operating Expenses is $1.8 million (2023), against an average of $14.2 million.
• Biggest YoY gain for Other Operating Expenses was 11800.0% in 2022; the steepest drop was 152.07% in 2022.
• Year by year, Other Operating Expenses stood at -$6.3 million in 2022, then soared by 142.86% to $2.7 million in 2023, then surged by 276.85% to $10.2 million in 2024, then plunged by 92.14% to $800000.0 in 2025, then soared by 4967.0% to $40.5 million in 2026.
• Per Business Quant, the three latest PTCT Other Operating Expenses figures stand at $40.5 million (Q1 2026), $800000.0 (Q1 2025), and $10.2 million (Q4 2024).